Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection

This study is currently recruiting participants.
Verified April 2013 by Peking University
Sponsor:
Collaborator:
Taiho Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Shen Lin, Peking University
ClinicalTrials.gov Identifier:
NCT01534546
First received: February 13, 2012
Last updated: April 15, 2013
Last verified: April 2013

February 13, 2012
April 15, 2013
March 2012
September 2014   (final data collection date for primary outcome measure)
3 year Disease Free Survival [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  1. perioperative chemotherapy of SOX is superior than postoperative SOX after D2 dissection in LAGC.
  2. Postoperative SOX is non inferior to XELOX.
Same as current
Complete list of historical versions of study NCT01534546 on ClinicalTrials.gov Archive Site
  • 5 year Overall Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    1. perioperative chemotherapy of SOX is superior than postoperative SOX after D2 dissection in LAGC.
    2. Postoperative SOX is non inferior to XELOX.
  • safety [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
    peri-operation morbidity, mortality, and other adverse events including chemotherapy related ones.
Same as current
Not Provided
Not Provided
 
Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection

Peri-operative treatment of locally advanced gastric cancer (LAGC) has always been argued by eastern and western scholars. For patients with clinical stage of cT4b/N+M0, or cT4aN+M0, the prognosis is rather poor, and the primary lesions might not be resectable at the time of diagnosis. MAGIC study has showed that pre-and post-operative chemotherapy with 3 cycles of ECF has increased 13% on 5yOS compared with surgery alone; However, eastern studies such as ACTS GC or CLASSIC showed that TS-1 monotherapy or XELOX (oxaliplatin/capecitabine) combination given as adjuvant chemotherapy for stage II or III patients after D2 surgery could achieve the significant survival benefit. So whether perioperative or post operative therapy is more beneficial for LAGC patients lacks of data supported by prospective study.

So in this prospective randomized phase III study, the investigators aim to compare the survival benefit as well as the safety for SOX (oxaliplatin/TS-1) as perioperative therapy versus SOX or XELOX as postoperative therapy after D2 dissection.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Gastric Carcinoma
  • Drug: Oxaliplatin capecitabine
    capecitabine:1000 mg/m2 ,bid, d1~14 oxaliplatin:130mg/m2,iv drip for 2h,d1
  • Drug: Oxaliplatin S-1
    S-1: 40~60mg bid,po, d1~14 (S-1:BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) oxaliplatin:130mg/m2,iv drip for 2h,d1
  • Drug: Oxaliplatin S-1
    S-1: 40~60mg bid,d1~14 (S-1:BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) oxaliplatin:130mg/m2,iv drip for 2h,d1 S-1 monotherapy as the same dose and schedule of the above
  • Active Comparator: arm A postoperative Oxaliplatin/capecitabine(XELOX)

    postoperative Oxaliplatin/capecitabine(XELOX) patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.

    capecitabine:1000 mg/m2 ,bid, d1~14 q3W oxaliplatin:130mg/m2,iv drip for 2h,d1,q3W 8 cycles (6 months)

    Intervention: Drug: Oxaliplatin capecitabine
  • Experimental: arm B: postoperative Oxaliplatin/S-1(SOX)

    postoperative Oxaliplatin/S-1(SOX) patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.

    S-1:40~60mg bid,d1~14 q3W oxaliplatin:130mg/m2,iv drip for 2h,d1,q3W 8 cycles (6 months)

    Intervention: Drug: Oxaliplatin S-1
  • Experimental: Arm C:postoperative Oxaliplatin /S-1(SOX)

    Postoperative Oxaliplatin /S-1(SOX) patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.

    Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)

    Intervention: Drug: Oxaliplatin S-1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1059
March 2017
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • sign written informed consent form
  • age ≥ 18 years
  • pathologically confirmed gastric or GEJ adenocarcinoma
  • disease at clinical stage of resectable or potentially resectable LAGC(T4a-b/N+M0)
  • No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy
  • Adequate organ function as defined below:

Hematologic ANC ≥ 1.5*109/l Hemoglobin ≥ 9 g/dl Platelets ≥ 100*109/l Hepatic Albumin ≥ 30g/l Serum bilirubin ≤ 1.5×ULN AST and ALT ≤ 2.5×ULN ALP ≤ 2.5×ULN TBIL ≤ 1.5×ULN Renal Serum Creatinine < 1.5 ULN

  • KPS ≥ 70
  • Adequate lung and heart function
  • Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women
  • Sexually active males or females willing to practice contraception during the study until 30 days after end of study.

Exclusion Criteria:

  • Refuse to provide blood/tissue sample;
  • With distant metastasis;
  • Sexually active males or females refuse to practice contraception during the study until 30 days after end of study.
  • Known hypersensitivity reaction or metabolic disorder to fluorpyrimidines or oxaliplatin;
  • ≥ grade 1 peripheral neuropathy;
  • History of organ transplantation(including autologous bone marrow transplantation and Peripheral stem cell transplantation);
  • Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment);
  • Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease;
  • Concurrent severe infection;
  • unable to swallow; (complete or incomplete)gastrointestinal obstruction; gastrointestinal bleeding; gastrointestinal perforation;
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al);
  • History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible;
  • Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency;
  • Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons;
Both
18 Years and older
No
Contact: zhang xiaotian, MD 86-10-88196561 zhangxtxx@gmail.com
Contact: li ziyu, MD 86-10-88196050 ligregory369@hotmail.com
China
 
NCT01534546
CGOG1003-RESOLVE, CGOG 1003
Yes
Shen Lin, Peking University
Peking University
Taiho Pharmaceutical Co., Ltd.
Not Provided
Peking University
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP